Session Details

[O4]Oral Presentations 4

Tue. Jul 7, 2026 4:35 PM - 5:38 PM JST
Tue. Jul 7, 2026 7:35 AM - 8:38 AM UTC
Ito Hall( Ito International Research Center B2)
Chair:Yuki Furuse, Michiko Koga

[O4-01]Opened Aqueous Two-Phase Separation System for Integrated Single-Molecule Digital RNA Detection

*Hiroyuki Noji1 (1. Department of Applied Chemistry, Graduate school of Engineering, The University of Tokyo (Japan))
Comment()

[O4-02]Structural Biology and Synthetic Biology Approaches to Combatting Viral Pandemics

*Osamu Nureki1, Kanata Matsumoto1, Kazuhiro Sawada1, Shoma Sato1, Yoshimasa Takahashi3, Kei Sato2, Yoshihiro Kawaoka2, Yoshiaki Kise1 (1. Department of Biological Sciences, Graduate School of Science, The University of Tokyo (Japan), 2. The Institute of Medical Science, The University of Tokyo (Japan), 3. National Institute of Infectious Diseases (Japan))
Comment()

[O4-03]Integrative Analysis of Influenza Virus Evolution Using Protein Sequence and Structural Information

*Asato Kojima1, Jumpei Ukita1, Yutaka Matsuo1 (1. Matsuo-Iwasawa lab, Graduate School of Engineering, The University of Tokyo (Japan))
Comment()

[O4-04]Multi-scale information analysis for pandemic preparedness: integrating flight data, nighttime light imagery, and IoT contact data

*Daisuke Yoneoka1 (1. Japan Institute for Health Security (Japan))
Comment()

[O4-05]Evolution of Vaccine Hesitancy and Public Readiness for Future Pandemics

*Yuki Furuse1 (1. The UTOPIA Center, University of Tokyo (Japan))
Comment()

[O4-06]Using IoT Sensing to Characterize Human Contact Patterns in Indoor Environments

*Ryo Kinoshita1 (1. Department of Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))
Comment()

[O4-07]Toward the Ethical Development of Medical Countermeasures during Public Health Emergencies

*Kaori Muto1 (1. Department of Public Policy, The Institute of Medical Science, The University of Tokyo (Japan))
Comment()

[O4-08]A phase 1 clinical trial of a new oncolytic herpes virus expressing anti-VEGF antibody in patients with malignant glioma

*Tomoki Todo1, Hirotaka Ito1, Minoru Tanaka1 (1. Institute of Medical Science, The University of Tokyo (Japan))
Comment()

[O4-09]Clinical Research at UTOPIA, Including Clinical Trials

*Michiko Koga1,2 (1. the UTOPIA Center, the University of Tokyo (Japan), 2. IMSUT Hospital, the Institute of Medical Science, the University of Tokyo (Japan))
Comment()